Finerenone, a nonsteroidal mineralocorticoid receptor antagonist, demonstrated consistent efficacy and safety regardless of diuretic type or dose and reduced overall diuretic requirements in patients ...

CHICAGO — A nasal spray formulation of bumetanide, a diuretic drug, could help treat heart failure by preventing the resistance that can develop to oral forms of the drug, a preliminary safety and ...

The US Food and Drug Administration (FDA) has approved the first intranasal diuretic for heart, liver and kidney disease patients, aiming to prevent a common and costly issue that results in more than ...

A recent study co-authored by Dr. Matthew Segar, a third-year cardiovascular disease fellow at The Texas Heart Institute and led by his research and residency mentor, University of Texas Southwestern ...

Please provide your email address to receive an email when new articles are posted on . Researchers found a notable interaction based on patients' prior history of kidney stones. Hypokalemia was more ...

What Is Enbumyst, and Why Does It Matter? Enbumyst is a new nasal spray form of bumetanide (first approved by the FDA in 1983). It is a type of medicine called a loop diuretic (also known as a “water ...

In the U.S., sudden cardiac deaths have been on a sharp upward trajectory since 2018. (Journal of the American Heart Association) For New Yorkers discharged after a heart failure exacerbation, a ...